Navigation Links
Cancer Vaccines Poised to Reach $3 Billion in Sales by 2015

FALLS CHURCH, Va., April 19, 2011 /PRNewswire/ -- Technology Catalysts International (TCI), leading global consultants to the pharmaceutical industry, announced that research on cancer trends and development has identified cancer vaccines as a viable treatment option for a variety of cancers that currently have ineffective treatments.  The potential of the cancer vaccine market is forecast to approach $3 billion in 2015.

With the Medicare advisory committee's recent recommendation to support Dendreon's expensive prostate cancer vaccine, Provenge®, the field of cancer vaccines has received an unprecedented boost.  As a result, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. Prophylactic cancer vaccines, Gardasil® by Merck and Cervarix® by GSK, have already gained worldwide attention with their blockbuster status/potential.

Dr. Joseph Pantginis of Roth Capital Partners, a full service investment banking firm, recently evaluated the BiovaxID® technology from Biovest International and believes that this vaccine will be the next success, even though there are certain risks involved including the path to market for BiovaxID. However, in spite of the risks, Dr. Pantginis feels cancer immunology is coming of age and that BiovaxID can be successful even when two prior idiotype vaccines (developed by Genitope and Favrille) have failed.  According to Dr. Pantginis, there are two main reasons why BiovaxID is believed to have succeeded where the others have failed 1) critical data at the ASH 2010 conference were presented demonstrating that a vaccine against IgM and not igG is the reason for BiovaxID's success and 2) BiovaxID uses the entire idiotype from a patient to manufacture the vaccine whereas Genitope and Favrille used recombinant portions of the idiotype.

The greatest challenges to a successful vaccine development program are seeking the right antigen, selecting the right adjuvant, and developing an effective targeting technology.  Technology Catalysts' newly-released Cancer Vaccines report profiles companies that are developing novel approaches to successfully create effective cancer vaccines and overcome these hurdles.

To leapfrog the development process and enter into strategic alliances, the report provides detailed descriptions of more than 35 companies that have active developments in various approaches to cancer vaccines and are open to strategic alliances. The report also analyzes the current technology and market potential for cancer vaccines and features a pipeline overview, market analysis, and a summary of recent deals associated with cancer vaccines. In addition, the report provides detailed descriptions of novel technologies designed for the development of cancer vaccines. The information is confirmed via company interviews and includes full contact information for easy follow-up and business development opportunities.

A complimentary excerpt of this report is available for download at:

About Technology Catalysts International:

Technology Catalysts International ("TCI") was founded in 1979 and provides consulting services in technology transfer and business research. The company specializes in technology licensing, technology assessment, and business intelligence. With a focus on pharmaceuticals, drug delivery, consumer healthcare, and advanced materials/processes, TCI's core consulting services are based on continuous monitoring of technological product development activities on a global basis.  TCI is headquartered in the US and has offices in the UK, Germany, Czech Republic, China, Korea, Japan, India, and Latin America.

Ajay Rastogi, Vice President
Technology Catalysts International
Telephone (703) 531-0257

SOURCE Technology Catalysts International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
Breaking Medicine Technology:
(Date:11/26/2015)... Bangalore, Karnataka (PRWEB) , ... ... ... an innovative online platform for mental health and wellness consultation, has collaborated ... self-empowerment, to holistically address their reader’s queries on topics on mental and ...
(Date:11/25/2015)... Indianapolis, IN (PRWEB) , ... November 25, 2015 ... ... clean water accessible for all, Water For Empowerment ™ attracts volunteers together ... on clean water by empowering women as key stakeholders in the process. The ...
(Date:11/25/2015)... Neb. (PRWEB) , ... November 25, 2015 , ... ... staffing companies, has been recognized once again for its stellar workplace culture with ... to Work.” , Medical Solutions’ Cincinnati office was named a finalist ...
(Date:11/25/2015)... ... , ... Ministers, senior government and UN agencies, representatives from ... Excellence, and public R&D institutions, civil societies and other partners gathered today at ... Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day meeting ...
(Date:11/25/2015)... Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... da Vinci surgical robot is being more and more widely heralded as a breakthrough ... assisted da Vinci method has over traditional laparoscopic surgery is that it can greatly ...
Breaking Medicine News(10 mins):